Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: TCG Crossover GP III, LLC

June 3, 2026 4:17 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of (a) 11,111,111 shares of Common Stock and (b) 4,687,888 shares of Common Stock underlying Common Stock Warrants (the Common Stock Warrants) which are exercisable within 60 days of this Statement. These securities are held of record by TCG Crossover III (as defined in Item 2(a) below). This total excludes 6,423,223 shares of Common Stock subject to Common Stock Warrants which are not exercisable within 60 days of this Statement because the Common Stock Warrants may not be exercised for Common Stock to the extent that doing so would result in the holder of the Common Stock Warrants (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) beneficially owning more than 9.99 percent of the shares of Common Stock then outstanding immediately after giving effect to such exercise (the Beneficial Ownership Limitation). TCG Crossover GP III (as defined in Item 2(a) below) is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 158,149,726 shares, as follows: (a) 153,461,838 shares of Common Stock outstanding as of May 27, 2026, following the underwritten offering that closed on May 27, 2026 (the Offering), as reported by the Issuer (as defined in Item 1(a) below) in its final prospectus filed with the United States Securities and Exchange Commission (the Commission) on May 26, 2026 (the Prospectus), plus (b) 4,687,888 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of (i) 11,111,111 shares of Common Stock and (ii) 4,687,888 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement. These securities are held of record by TCG Crossover III. This total excludes 6,423,223 shares of Common Stock subject to Common Stock Warrants which are not exercisable for Common Stock within 60 days of this Statement due to the Beneficial Ownership Limitation. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 158,149,726 shares, as follows: (a) 153,461,838 shares of Common Stock outstanding as of May 27, 2026, following the Offering, as reported by the Issuer in the Prospectus, plus (b) 4,687,888 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of (i) 11,111,111 shares of Common Stock and (ii) 4,687,888 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement. These securities are held of record by TCG Crossover III. This total excludes 6,423,223 shares of Common Stock subject to Common Stock Warrants which are not exercisable for Common Stock within 60 days of this Statement due to the Beneficial Ownership Limitation. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 158,149,726 shares, as follows: (a) 153,461,838 shares of Common Stock outstanding as of May 27, 2026, following the Offering, as reported by the Issuer in the Prospectus, plus (b) 4,687,888 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement.


SCHEDULE 13G



TCG Crossover GP III, LLC
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, Authorized Signatory
Date:06/03/2026
TCG Crossover Fund III, L.P.
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, Authorized Signatory
Date:06/03/2026
Chen Yu
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, as Attorney-in-Fact for Chen Yu
Date:06/03/2026
Exhibit Information

Exhibit 1 - Joint Filing Agreement

ATTACHMENTS / EXHIBITS

EX-99.1

Categories

SEC Filings